Kansè nan tete se yon maladi grav e ki ka touye moun.
Se kansè ki pi komen nan mitan fanm atravè lemond e dezyèm kòz ki mennen nan lanmò kansè nan fanm.
Dapre Sosyete Kansè Ameriken an, nan 20220, yo te estime 276,480 nouvo ka kansè nan tete pwogrese nan fanm nan Etazini, ak apeprè 42,170 fanm nan Etazini te mouri nan kansè nan tete.
Sepandan, to mòtalite nan kansè nan tete te diminye depi 1989, avèk yon diminisyon 40% nan to mòtalite kansè nan tete soti nan 1989 pou rive 2017, lajman akòz amelyorasyon nan deteksyon bonè ak tretman.
Risk pou mouri nan kansè nan tete varye selon faktè tankou laj, etap nan dyagnostik, ak kalite kansè nan tete.
Si yo detekte l byen bonè epi yo ba l tretman, sa ka fè l viv pi lontan.
van Schoor G, Moss SM, Otten JD, Donders R, Paap E, den Heeten GJ, Holland R, Broeders MJ, Verbeek AL: Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer. 2011, 104 (6): 910-4.
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL: Breast cancer statistics, 2019. CA Cancer J Clin. 2019, 69 (6): 438-451.
Icaza G, Núñez L, Bugueño H: [Epidemiological analysis of breast cancer mortality in women in Chile]. Rev Med Chil. 2017, 145 (1): 106-114.
Monticciolo DL, Newell MS, Hendrick RE, Helvie MA, Moy L, Monsees B, Kopans DB, Eby PR, Sickles EA: Breast Cancer Screening for Average-Risk Women: Recommendations From the ACR Commission on Breast Imaging. J Am Coll Radiol. 2017, 14 (9): 1137-1143.
Deaths from breast cancer--United States, 1991. MMWR Morb Mortal Wkly Rep. 1994, 43 (15): 273, 279-81.
Kuroishi T, Hirose K, Suzuki T, Tominaga S: Effectiveness of mass screening for breast cancer in Japan. Breast Cancer. 2000, 7 (1): 1-8.
['Avètisman: medikal']
['Sit entènèt sa a se pou rezon edikasyonèl ak enfòmasyon sèlman e li pa bay konsèy medikal oswa sèvis pwofesyonèl.']
['Enfòmasyon yo bay la pa dwe itilize pou fè dyagnostik oswa trete yon pwoblèm sante oswa maladi, e moun k ap chèche konsèy medikal pèsonèl ta dwe konsilte yon doktè ki gen lisans.']
['Tanpri note ke rezo neural ki jenere repons pou kesyon yo, pa egzat sitou lè li rive pou kontni nimerik. pa egzanp, kantite moun ki te dyagnostike ak yon maladi espesifik.']
['Toujou chèche konsèy doktè ou oswa lòt founisè sante ki kalifye konsènan yon kondisyon medikal. Pa janm meprize konsèy medikal pwofesyonèl oswa reta nan chèche li paske nan yon bagay ou te li sou sit entènèt sa a. Si ou panse ou ka gen yon ijans medikal, rele 911 oswa ale nan sal ijans ki pi pre a imedyatman. Pa gen okenn relasyon doktè-pasyan ki kreye pa sit entènèt sa a oswa itilizasyon li yo. Ni BioMedLib ni anplwaye li yo, ni okenn kontribitè nan sit entènèt sa a, fè okenn reprezantasyon, eksprime oswa enplisit, ki gen rapò ak enfòmasyon yo bay isit la oswa pou itilize li yo.']
['Avètisman: dwa otè']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) bay rekou pou mèt copyright ki kwè ke materyèl ki parèt sou entènèt la vyole dwa yo anba lwa copyright Etazini. ']
['Si ou kwè ak tout konfyans ke nenpòt kontni oswa materyèl ki disponib an koneksyon avèk sit entènèt nou an oswa sèvis vyole copyright ou, ou (oswa ajan ou) ka voye nou yon avi pou mande pou retire kontni an oswa materyèl la, oswa aksè a li bloke.']
['Anons yo dwe voye alekri pa imel (gade seksyon "Kontak" pou adrès imel)']
['DMCA mande pou avi ou sou vyolasyon dwa otè a genyen enfòmasyon sa yo: (1) deskripsyon travay ki gen dwa otè a ki sijè vyolasyon an; (2) deskripsyon kontni ki vyole dwa otè a ak enfòmasyon ki sifi pou pèmèt nou jwenn kontni an; (3) enfòmasyon pou kontakte ou, ki gen ladan adrès ou, nimewo telefòn ou ak adrès imel ou; (4) yon deklarasyon ou fè ki di ou gen bon lafwa ke kontni an nan fason ou pote plent la pa otorize pa mèt pwopriyete dwa otè a, oswa ajan li, oswa pa operasyon nenpòt lwa; ']
['(5) yon deklarasyon ou siyen sou penalite fo temwayaj ke enfòmasyon ki nan notifikasyon an egzat e ke ou gen otorite pou fè respekte dwa otè yo ke yo reklame ke yo vyole yo;']
['e (6) yon siyati fizik oubyen elektwonik mèt copyright la oubyen yon moun ki otorize pou aji sou non mèt copyright la. ']
['Si ou pa bay tout enfòmasyon ki anwo yo, sa ka fè ke nou pa trete plent ou a byen vit.']
['Kontak']
['Tanpri voye nou yon imèl avèk nenpòt kesyon / sijesyon.']
How deadly is breast cancer?
Breast cancer is a serious and potentially deadly disease.
It is the most common cancer among women worldwide and the second leading cause of cancer death in women.
According to the American Cancer Society, in 20220, an estimated 276,480 new cases of invasive breast cancer were diagnosed in women in the United States, and about 42,170 women in the U.S. died from breast cancer.
However, the death rate from breast cancer has been declining since 1989, with a 40% decrease in the breast cancer death rate from 1989 to 2017, largely due to improvements in early detection and treatment.
The risk of dying from breast cancer varies depending on factors such as age, stage at diagnosis, and the type of breast cancer.
Early detection and treatment can significantly improve the chances of survival.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['sou']
['BioMedLib itilize òdinatè otomatik (algoritm aprantisaj machin) pou jenere pè kesyon ak repons.']
['Nou kòmanse ak 35 milyon piblikasyon biomedik de PubMed/Medline. tou, paj entènèt de RefinedWeb.']
